Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | XL228 |
Synonyms | |
Therapy Description |
XL228 inhibits multiple tyrosine kinases, including the insulin-like growth factor 1 receptor (IGF1R), Src tyrosine kinase, and Bcr-Abl tyrosine kinase, which can lead to cell growth inhibition (Mol Cancer Ther 2009;8(12 Suppl):C192, PMID: 20557276). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
XL228 | BCR-ABL Inhibitor 31 IGF-1R Inhibitor 17 SRC Inhibitor 31 | XL228 inhibits multiple tyrosine kinases, including the insulin-like growth factor 1 receptor (IGF1R), Src tyrosine kinase, and Bcr-Abl tyrosine kinase, which can lead to cell growth inhibition (Mol Cancer Ther 2009;8(12 Suppl):C192, PMID: 20557276). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|